Solid Biosciences (SLDB) Cash from Operations Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 74.39% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.23% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 158.60% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -48.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.29% |
| Dec 31, 2025 | -80.65% |
| Sep 30, 2025 | -41.18% |
| Jun 30, 2025 | -74.28% |
| Mar 31, 2025 | -26.43% |
| Dec 31, 2024 | -42.37% |
| Sep 30, 2024 | -32.47% |
| Jun 30, 2024 | 21.84% |
| Mar 31, 2024 | 10.01% |
| Dec 31, 2023 | 39.61% |
| Sep 30, 2023 | 12.39% |
| Jun 30, 2023 | -72.98% |
| Mar 31, 2023 | -2.96% |
| Dec 31, 2022 | -65.18% |
| Sep 30, 2022 | -10.88% |
| Jun 30, 2022 | 7.15% |
| Mar 31, 2022 | -27.26% |
| Dec 31, 2021 | -1,697.09% |
| Sep 30, 2021 | -18.38% |
| Jun 30, 2021 | -30.85% |
| Mar 31, 2021 | 27.01% |
| Dec 31, 2020 | 106.15% |
| Sep 30, 2020 | 19.11% |
| Jun 30, 2020 | 50.31% |
| Mar 31, 2020 | -12.91% |
| Dec 31, 2019 | 0.74% |
| Sep 30, 2019 | -25.84% |
| Jun 30, 2019 | -61.05% |
| Mar 31, 2019 | -50.98% |
| Dec 31, 2018 | -53.08% |
| Sep 30, 2018 | -61.99% |
| Jun 30, 2018 | -69.99% |
| Mar 31, 2018 | -68.42% |